Dolutegravir

Published November 04, 2012; Updated October 07, 2014
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-03
Selected Reference
5. Castagna A, Maggiolo F, Penco G, et al; VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014 Aug 1;210(3):354-62.